PD-1 Inhibitors in Recurrent or Metastatic Oral Squamous Cell Carcinoma: Clinical Evidence, Patient Selection, and Immune-Related Toxicities. Journal of Oral Health and Dental Therapeutics, v. 1, n. 1, p. 27–31, 30 Oct.2026.